I期临床-话题@MedSci

#I期临床#

570篇内容 | 7026人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653184, encodeId=9548165318431, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, objectType=article, longId=211358, objectId=b3ef2113580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ef2113580f, replyNumber=0, likeNumber=0, createdTime=2021-07-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ef2113580f, moduleTitle=J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ef2113580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653118, encodeId=d617165311839, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, objectType=article, longId=203072, objectId=4a132030e2bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a132030e2bd, replyNumber=0, likeNumber=57, createdTime=2021-03-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a132030e2bd, moduleTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a132030e2bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653152, encodeId=58201653152e2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验, objectType=article, longId=206287, objectId=c78320628e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78320628e43, replyNumber=0, likeNumber=27, createdTime=2021-05-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78320628e43, moduleTitle=济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78320628e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653199, encodeId=244b1653199e5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点, objectType=article, longId=216297, objectId=88e921629ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88e921629ef3, replyNumber=0, likeNumber=69, createdTime=2022-01-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88e921629ef3, moduleTitle=恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88e921629ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653125, encodeId=135e16531259d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=68, createdTime=2021-03-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653141, encodeId=35141653141f6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, objectType=article, longId=204977, objectId=9fff2049e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fff2049e7bf, replyNumber=0, likeNumber=66, createdTime=2021-04-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fff2049e7bf, moduleTitle=新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fff2049e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653179, encodeId=446416531e9ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, objectType=article, longId=210493, objectId=d849210493a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d849210493a6, replyNumber=0, likeNumber=84, createdTime=2021-12-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d849210493a6, moduleTitle=特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d849210493a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653119, encodeId=d1811653119cf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, objectType=article, longId=203078, objectId=c59e2030e858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c59e2030e858, replyNumber=0, likeNumber=88, createdTime=2021-07-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c59e2030e858, moduleTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c59e2030e858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653106, encodeId=c08e165310624, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性, objectType=article, longId=201996, objectId=1f8e201996f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8e201996f6, replyNumber=0, likeNumber=64, createdTime=2021-07-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8e201996f6, moduleTitle=X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f8e201996f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653121, encodeId=e5061653121d0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, objectType=article, longId=203249, objectId=a99020324958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a99020324958, replyNumber=0, likeNumber=57, createdTime=2021-01-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a99020324958, moduleTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a99020324958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653105, encodeId=7661165310527, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, objectType=article, longId=201995, objectId=a7e920199565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e920199565, replyNumber=0, likeNumber=0, createdTime=2021-09-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e920199565, moduleTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e920199565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653114, encodeId=e3d7165311400, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, objectType=article, longId=202653, objectId=fcf72026535d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcf72026535d, replyNumber=0, likeNumber=74, createdTime=2020-11-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcf72026535d, moduleTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcf72026535d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, objectType=article, longId=202450, objectId=e82920245051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82920245051, replyNumber=0, likeNumber=57, createdTime=2021-06-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82920245051, moduleTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e82920245051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653101, encodeId=ca691653101e3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , objectType=article, longId=201778, objectId=df60201e785f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df60201e785f, replyNumber=0, likeNumber=54, createdTime=2020-10-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df60201e785f, moduleTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df60201e785f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653186, encodeId=9a48165318652, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=60, createdTime=2021-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653107, encodeId=02b1165310e62, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, objectType=article, longId=201999, objectId=9dcd20199981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd20199981, replyNumber=0, likeNumber=68, createdTime=2021-04-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd20199981, moduleTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd20199981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653167, encodeId=aff3165316e2f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, objectType=article, longId=208482, objectId=a52b208482ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52b208482ca, replyNumber=0, likeNumber=81, createdTime=2021-05-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52b208482ca, moduleTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52b208482ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=61, createdTime=2021-09-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653094, encodeId=662e165309496, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=93, createdTime=2021-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653190, encodeId=c3911653190f9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, objectType=article, longId=212433, objectId=8b68212433dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b68212433dd, replyNumber=0, likeNumber=78, createdTime=2021-06-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b68212433dd, moduleTitle=NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b68212433dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Thorac Oncol: Capmatinib治疗既往应用过MET抑制剂的肺癌的疗效：一项II期临床试验

2021-07-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验

2021-03-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

济民可信新冠病毒特异性中和抗体JMB2002启动I期临床试验

2021-05-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

恒瑞医药SHR0302片治疗斑秃II期临床达到主要研究终点

2022-01-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2021-03-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

新加坡卫生科学局批准继续进行ARCT-021（LUNAR-COV19）疫苗的II期临床研究

2021-04-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

特瑞普利单抗一线治疗食管癌III期临床研究达到主要研究终点

2021-12-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据

2021-07-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性

2021-07-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停

2021-01-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败

2021-09-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验

2020-11-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持

2021-06-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？

2020-10-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-12-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性

2021-04-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点

2021-05-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-09-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验

2021-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：5价脑膜炎奈瑟菌疫苗NmCV-5 II期临床研究获得成功

2021-06-21

科室
- - 订阅+
  - 更多科室
工具
服务